U.S. markets closed
  • S&P Futures

    4,258.75
    +4.00 (+0.09%)
     
  • Dow Futures

    34,380.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    14,140.50
    +15.75 (+0.11%)
     
  • Russell 2000 Futures

    2,324.10
    +0.50 (+0.02%)
     
  • Crude Oil

    71.17
    +0.29 (+0.41%)
     
  • Gold

    1,862.20
    -3.70 (-0.20%)
     
  • Silver

    27.75
    -0.28 (-1.01%)
     
  • EUR/USD

    1.2121
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.5010
    +0.0390 (+2.67%)
     
  • Vix

    16.39
    +0.74 (+4.73%)
     
  • GBP/USD

    1.4101
    -0.0007 (-0.05%)
     
  • USD/JPY

    110.1300
    +0.0690 (+0.06%)
     
  • BTC-USD

    40,008.54
    +880.11 (+2.25%)
     
  • CMC Crypto 200

    1,001.13
    +32.29 (+3.33%)
     
  • FTSE 100

    7,146.68
    +12.62 (+0.18%)
     
  • Nikkei 225

    29,390.91
    +229.11 (+0.79%)
     

Recap: Arbutus Biopharma Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 6.0% in pre-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 50.00% year over year to ($0.23), which missed the estimate of ($0.22).

Revenue of $2,386,000 higher by 47.47% year over year, which beat the estimate of $1,960,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Mar 04, 2021

View more earnings on ABUS

Time: 08:45 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/kv9k7xnj

Recent Stock Performance

52-week high: $9.02

52-week low: $0.88

Price action over last quarter: Up 22.58%

Company Profile

Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.